

NEW Salbutamol Plus for Performance Plus

COMBIVENT

Salbutamol + ipratropium bromide *In a single metered dose inhaler*

Prescribing information Combivent MDI Metered Dose Inhaler containing 200 doses, each delivering ipratropium bromide (anticholinergic bronchodilator) 20 micrograms and salbutamol (β_2-adrenergic agonist) 100 micrograms. **Indication:** treatment of bronchospasm associated with chronic obstructive pulmonary disease in patients who require regular treatment with both ipratropium and salbutamol. **Dosage:** Adults only: two puffs four times a day. **Contra-indication:** known hypersensitivity to any of the components or to atropine or its derivatives. **Precautions:** cardiac disorders; hyperthyroidism; diabetes mellitus; co-prescription with β-blockers, corticosteroids, xanthine derivatives, other β-agonists or anticholinergics; pregnancy, especially the first trimester, and breast feeding. Potentially serious hypokalaemia may result from β_2-agonist therapy. Advise patient to seek medical advice in the event of acute, rapidly worsening dyspnoea or if response lessens; do not spray into the eye. **Side-effects:** tremor and nervousness may occur; tachycardia, dizziness, palpitations, headache, local reactions such as dryness of the mouth are less frequent; urinary retention has been reported rarely. As with other bronchodilators, cough and, very rarely, paradoxical bronchoconstriction have been observed. **Basic NHS price** 10ml vial complete with mouthpiece UK £6.00 POM. PL 0015/0191. PA 7/52/1 **Product Licence and Authorisation Holder:** Boehringer Ingelheim Limited, Ellesfield Avenue, Bracknell, RG12 8YS. **Date of Preparation:** March 1994. For full prescribing information please see data sheet.

Boehringer Ingelheim

Prepared March 1994.

ASTRA

Time to take a breather from oral steroids

Pulmicort
BUDESONIDE
Respules

A high-dose nebulised steroid that's low on side effect

"I sleep well"



Twice daily

SEREVENT

salmeterol xinafoate

FOR ACTIVE DAYS AND RESTFUL NIGHTS

Serevent (salmeterol xinafoate)
Abridged Prescribing Information
(Please refer to the full data sheet before prescribing)
Uses Treatment of asthma (including nocturnal and exercise-induced) in patients requiring long-term regular bronchodilator therapy. Patients should normally also be receiving regular and adequate doses of inhaled anti-inflammatory agents, or oral corticosteroids. **Dosage and administration** For inhalation only. *Adults and children 4 years and over:* 50 micrograms twice daily. *Adults only:* More severe cases 100 micrograms twice daily. *Children below 4 years:* Not recommended at present. **Contra-indication** Hypersensitivity. **Precautions** *Steroid therapy:* Serevent is not a replacement for corticosteroids and/or, in children, sodium cromoglycate. Warn patients not to stop or reduce such therapy. *Severe or unstable asthma:* Bronchodilators should not be the only or main treatment. Consider using oral steroids and/or maximum doses of inhaled corticosteroids. Warn patients to seek medical advice if short-acting bronchodilator use increases or becomes less effective. Treat severe exacerbations in the normal way. *Acute symptoms:* Serevent is not for relief of acute symptoms. A short-acting inhaled bronchodilator is required. *Thyrotoxicosis:* Use with caution. *Drug interactions:* Avoid beta-blockers. *Hypokalaemia:* May occur, particularly in acute severe asthma. It may be potentiated by xanthine derivatives, steroids, diuretics and hypoxia. Monitor serum potassium levels in these situations. *Pregnancy and lactation:* Experience is limited. Balance risks against benefits. **Side effects** Tremor, subjective palpitations and headaches have been reported, but are usually mild and transient. Skin reactions, muscle cramps, non-specific chest pain, local irritation and arthralgia have been reported. Potentially serious hypokalaemia may result from β_2-agonist therapy. *Paradoxical bronchospasm:* Substitute alternative therapy. **Presentation and Basic NHS cost** *Serevent Diskhaler:* Pack of 14 four-place disk foils, together with a Serevent Diskhaler, 50 micrograms – £29·97. *Serevent Diskhaler refill pack:* Pack of 14 four-place disk foils only – £29·40. *Serevent Inhaler:* 120 actuations per inhaler, 25 micrograms – £28·60. Hospital packs are also available. **Product licence numbers** 0045/0158, 0045/0157.

POM

ALLEN & HANBURYS

Further information is available on request from:
Allen & Hanburys Limited
Uxbridge, Middlesex UB11 1BT

Diskhaler and Serevent are trade marks of the Glaxo Group of Companies

September 1993

When introducing Serevent in adults we strongly recommend that you do not stop or reduce the dose of corticosteroids. Similarly, in children, do not stop or reduce corticosteroids or sodium cromoglycate.



AEROBEC 50 AUTOHALER, AEROBEC 100 AUTOHALER AND AEROBEC FORTE AUTOHALER ABBREVIATED PRESCRIBING INFORMATION

Presentation: Breath-actuated pressurized inhalation aerosols delivering 50mcg (AeroBec 50), 100mcg (AeroBec 100) or 250mcg (AeroBec Forte) of beclomethasone dipropionate (as propellent solvate) into the mouthpiece of a breath-actuated adapter. **Indications:** For the prophylactic treatment of chronic reversible obstructive airways disease. AeroBec Forte is indicated for those patients who require high doses of beclomethasone to control their symptoms. **Dosage: AeroBec 50, 100:** *Adults:* 200mcg twice daily or 100mcg three or four times daily. In more severe cases a dose of 600-800mcg is recommended, with subsequent reductions. Maximum recommended daily dose of these preparations is 1000mcg. Adrenal suppression may occur in patients receiving doses of 1500mcg or more daily. *Children:* 50-100mcg two to four times daily. **AeroBec Forte:** *Adults:* two inhalations (500mcg) twice daily, increasing to a maximum of two inhalations four times daily if necessary. Adrenal suppression may occur in patients receiving 1500mcg or more daily. *Children:* not recommended. **Contra-indications:** Hypersensitivity to beclomethasone. Caution in patients with pulmonary tuberculosis. **Side-effects:** Candidiasis of throat or mouth. Hoarseness. **Precautions:** Patients with adrenocortical suppression should have systemic steroids withdrawn slowly when converting to AeroBec therapy. During periods of stress or when asthma worsens supplementary systemic steroids may be needed. Discontinuation of systemic steroids may cause exacerbation of other allergic diseases. **Pregnancy:** There is inadequate evidence of safety in human pregnancy. Use should be avoided unless benefits outweigh risks. **Lactation:** Beclomethasone is probably excreted in milk. In breast-feeding mothers the therapeutic benefits of the drug should be weighed against the potential hazards to mother and baby. **Pharmaceutical precautions:** Store in a cool place protected from frost and direct sunlight. As the vial is pressurized, no attempt should be made to puncture it or dispose of it by burning. **Basic NHS prices:** AeroBec 50 : £11.00 AeroBec 100 : £13.50 AeroBec Forte : £25.10. **Product licence numbers:** AeroBec 50: PL 68/0143 AeroBec 100: PL 68/0145 AeroBec Forte: PL 68/0140. **Legal Category:** POM.

AEROLIN AUTOHALER ABBREVIATED PRESCRIBING INFORMATION

Presentation: A breath-actuated pressurized inhalation aerosol delivering Salbutamol Sulphate BP equivalent to salbutamol 100mcg. **Indications:** For the treatment of reversible airways obstruction associated with asthma, bronchitis and emphysema. **Dosage:** *Adults of all ages:* one or two inhalations as a single dose for acute symptomatic relief. For chronic maintenance/ prophylactic therapy, two inhalations three or four times daily. *Children:* half of adult dose, increasing as necessary to the full adult dose. **Precautions:** Administer cautiously to patients with thyrotoxicosis. Patients should be advised to seek medical advice if treatment ceases to be effective. **Side-effects:** Mild tremor, headache and transient muscle cramps may rarely occur. Potentially serious hypokalaemia has been reported in patients taking β_2-agonist therapy. **Pharmaceutical precautions:** Store in a cool place protected from frost and direct sunlight. As the vial is pressurized no attempt should be made to puncture it or dispose of it by burning. **Basic NHS price:** £10.51. **Product licence number:** PL 68/0117. **Legal Category:** POM.

Date of preparation of advertisement: February 1994

Further information is available from the 3M Health Care Information Scientist: Telephone Loughborough (0509) 611611. Pharmaceutical Division, 3M Health Care, Loughborough, England

3M Health Care



Once an X-ray confirms your diagnosis of pneumonia you need to act quickly. Treatment with once a day ROCEPHIN can be started immediately, before the results of susceptibility tests are known.

With a clinical success rate of 89.7% (n=1,060),[1,2] ROCEPHIN provides effective treatment of pneumonia, with proven efficacy in both community acquired and nosocomial pneumonia.[3]

Once-a-day

▼Rocephin

References
1. Brown. R.B. and Sands. M., Curr. Ther. Res.(1989).**46** (2). 285-91.
2. Data On File. (GCR B-116 232). **3**. Niebuhr. H. *et al.* Chemotherapie Journal (1993). **2**. 28-35. **4**. Estimated current cash annual sales worldwide - Data on File. Roche Products Ltd.

Brief Prescribing Information

Indications: Pneumonia. septicaemia: meningitis: bone. skin and soft tissue infections: infections in neutropenic patients: gonorrhoea: peri-operative prophylaxis of infections associated with surgery. Treatment may be started before the results of susceptibility tests are known. **Dosage and Administration:** Rocephin should be administered by deep intramuscular injection. slow intravenous injection. or as a slow intravenous infusion. after reconstitution of the solution. **Adults and children 12 years and over:** Standard dosage -1g once daily. Severe infections - 2-4g normally once daily. Duration of therapy varies according to course of disease. Gonorrhoea - single dose of 250mg i.m. Peri-operative prophylaxis - usually single dose of 1g. colorectal surgery 2g in conjunction with a suitable agent against anaerobic bacteria. **Children under 12 years:** Standard dosage - 20-50mg/kg once daily. Severe infections - maximum 80mg/kg once daily. Doses of 50mg/kg or over should be given by slow intravenous infusion over at least 30 minutes. **Renal and hepatic impairment:** In the absence of hepatic impairment dose reduction is required only in severe renal failure (creatinine clearance <10ml/min). when the daily dose should be 2g or less. No dose reduction is required in liver damage provided renal function is intact. In severe renal impairment accompanied by hepatic insufficiency the plasma concentration should be determined at regular intervals and dosage adjusted. Serum concentrations should be monitored in dialysis. **Contra-indications, Warnings etc.** Cephalosporin hypersensitivity. Premature infants. Full-term infants during first six weeks of life. Safety in pregnancy has not been established. **Precautions:** Stated dose should not be exceeded. Caution in patients with a history of hypersensitivity (especially anaphylactic reaction) to penicillins or other non-cephalosporin beta-lactam antibiotics. Anaphylactic shock requires immediate countermeasures. Severe renal impairment accompanied by hepatic insufficiency (see Dosage). **Side-effects and Adverse Reactions:** Gastro-intestinal side-effects including loose stools. diarrhoea. nausea. vomiting. stomatitis and glossitis. Cutaneous reactions including maculopapular rash. pruritus. urticaria. oedema and erythema multiforme. Haematological reactions including anaemia (all grades). leucopenia. neutropenia. thrombocytopenia. eosinophilia. agranulocytosis. positive Coombs' test and prolongation of prothrombin time. Regular blood counts should be carried out during treatment. Other reactions include headache. dizziness. drug fever and transient elevations in liver function tests. Rarely: glycosuria. oliguria. haematuria. anaphylaxis and bronchospasm. Very rarely. precipitation of ceftriaxone calcium salt in unne in patients on higher than recommended dose. Reversible precipitates of calcium ceftriaxone have been detected by gallbladder sonograms. In symptomatic cases (which are rare). conservative non-surgical management is recommended. Superinfections with yeasts. fungi or other resistant organisms. Rare instances of pseudomembranous colitis. Injection site pain and local phlebitis. **Legal Category:** POM. **Presentations and Basic NHS Cost:** 250mg vials i.m. and i.v. (containing 250mg ceftriaxone) - £2.87. 1g vials i.m. and i.v. (containing 1g ceftriaxone) - £11.46. 2g vials for infusion (containing 2g ceftriaxone) - £22.92. **Product Licence Numbers:** PL 0031/0169 (250mg vials). PL 0031/0171 (1g vials). PL 0031/0172 (2g vials) **Product Licence Holder:** Roche Products Limited. PO Box 8. Welwyn Garden City. Hertfordshire. AL7 3AY. Full prescribing information is available on request.

J 738084 Date of preparation February 1994

Roche

A LIFE-SAVING SYSTEM FOR ASTHMATICS



Bricanyl® Turbohaler®
TERBUTALINE SULPHATE

Pulmicort® Turbohaler®200
BUDESONIDE

Abridged prescribing information: Presentation: Bricanyl Turbohaler. Dry powder inhaler delivering 0.5 mg terbutaline sulphate per actuation. **Uses** Relief and prevention of bronchospasm in bronchial asthma and bronchopulmonary disorders in which bronchospasm or reversible airways obstruction is a complicating factor. **Dosage and administration:** Adults and children (including elderly): One inhalation (0.5 mg) as required. Not more than 4 inhalations/day. **Contra-indications, warnings, etc:** Sensitivity to terbutaline sulphate. Precautions: Care should be taken in patients with myocardial insufficiency or thyrotoxicosis. Additional blood glucose measurements are initially recommended in diabetic patients. If treatment becomes less effective or shorter acting, the patient's general condition should be reviewed. Do not use in patients with hypertrophic cardiomyopathy. Potentially serious hypokalaemia may result from ß2-agonist therapy. Administer with caution during the first trimester of pregnancy. Do not administer concurrently with non-selective ß-blockers. Use with caution with other sympathomimetics. **Side effects:** Tremor, tonic cramp and palpitations are all characteristic of sympathomimetic amines. A few patients feel tense. **Basic NHS price:** Bricanyl Turbohaler (100 doses) £8.94. **Legal category:** POM. **Product licence number:** PL 0017/0241.

Presentations: Pulmicort Turbohaler 100. 100 µg/puff budesonide dry powder inhaler containing 200 doses. Pulmicort Turbohaler 200. 200 µg/puff budesonide dry powder inhaler containing 100 doses. Pulmicort Turbohaler 400. 400 µg/puff budesonide dry powder inhaler containing 50 doses. **Uses:** Bronchial asthma. **Dosage and administration:** Individualise dose. Adults: 200-1600 µg daily in divided doses. Children: 200-800 µg daily in divided doses. Maintenance: Use lowest possible dose. Brush the teeth and rinse the mouth out with water after each use. **Contra-indications, warnings, etc:** Active pulmonary tuberculosis. Special care is needed in patients with fungal and viral infections in the airways. Avoid administration during pregnancy. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to treatment with Pulmicort demands special care. See data sheet for further details. **Side effects:** Mild irritation in the throat, hoarseness and oral candidiasis occur in some patients. Rare cases of cataract have been reported after prolonged use of corticosteroids. **Legal category:** POM. **Basic NHS price:** Pulmicort Turbohaler 100 (200 doses) £18.50. Pulmicort Turbohaler 200 (100 doses) £18.50. Pulmicort Turbohaler 400 (50 doses) £18.50. **Product licence numbers:** Pulmicort Turbohaler 100 PL 0017/0319 (100 µg/puff). Pulmicort Turbohaler 200 PL 0017/0272 (200 µg/puff). Pulmicort Turbohaler 400 PL 0017/0271 (400 µg/puff).

ASTRA Astra Pharmaceuticals

Further information is available from the product licence holder: Astra Pharmaceuticals Limited, Home Park, Kings Langley, Herts WD4 8DH. ®Registered trade mark

Date of preparation: April 1994

DECISIVE ACTION

... Fortum/Saline Infusion Kit - ... ceftazidime ... 50ml ... Sodium ... Infusion, transfer ... swab, sealing cap ... The treatment of ... proven single and mixed ... caused by susceptible ... Fortum/Saline Infusion Kit - ... of 2g ceftazidime ... administration ... Data Sheet for details.) 1g to ... i.v. per day and by the i.p. route 125 to 250mg per 2L dialysis fluid. Most infections, 2g i.v. b.i.d.; severe infections, up to 6g i.v. per day. Cystic fibrosis - up to 9g i.v. per day in three divided doses. Dosage should be reduced when glomerular filtration <50ml/min. An initial 1g loading dose may be given with suspected renal insufficiency. *Elderly:* Daily dosage should not normally exceed 3g. *Neonates/Infants/Children:* (See Data Sheet for details.) Up to two months: 25 to 60mg/kg/day as two divided doses. Over two months: 30 to 100mg/kg/day as two or three divided doses. Cystic fibrosis, meningitis, immunocompromised: up to 150mg/kg/day (max 6g daily) in three divided doses. Sensitivity results are recommended before commencing meningitis monotherapy. The Infusion Kit, in the dosage presented, may not be appropriate for use in children. **Contra-indication** Known hypersensitivity to cephalosporins. **Precautions** Previous anaphylactic reaction to penicillin. Administer with caution in early pregnancy, infancy and with concurrent nephrotoxic drug treatment. Fortum is excreted in human milk in low concentrations. Slight interference with copper reduction methods may occur. Fortum and aminoglycosides should not be mixed in the same giving set or syringe. Prolonged use may cause overgrowth of non-susceptible organisms (e.g. Candida, Enterococci) which may require interruption of treatment or other measures. **Side effects** Adverse reactions occur infrequently; pain and/or inflammation (i.m.) and phlebitis and/or thrombophlebitis (i.v.), rashes, fever, pruritus, anaphylaxis, GI disturbances, headache, dizziness, paraesthesia and bad taste. Transient changes in laboratory values may occur: eosinophilia, positive Coombs' test, thrombocytosis, leucopenia, neutropenia, thrombocytopenia and slight rises in hepatic enzymes. **Basic NHS cost** Packs of vials for injection (5 x 250mg, 5 x 500mg, 5 x 1g, 5 x 2g), and an infusion pack (5 x 2g); £9·90 per gram. Fortum/Saline Infusion Kit; £20·82. **Product licence numbers** Fortum for Injection: 250mg: 0004/0304; 500mg: 0004/0292; 1g: 0004/0293; 2g: 0004/0294. Sodium Chloride Intravenous Infusion: 3460/0015. **Product licence holder** Fortum for Injection: Glaxo Operations UK Limited, Greenford, Middlesex UB6 0HE. Sodium Chloride Intravenous Infusion: Galen Research Ltd, Craigavon, Northern Ireland BT63 5UA. POM

FORTUM
ceftazidime

Glaxo

Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 1BT Tel: 081-990 9444.
Fortum is a Glaxo trade mark
December 1993

Peregrine falcon

OSTEO-REGENERATION

Until recently little could be done to treat established vertebral osteoporosis.

Now, through the power of osteo-regeneration, Didronel PMO enables you to reduce vertebral fractures by actually rebuilding lost bone mass.[1,2]

Isn't it time you discovered the power of osteo-regeneration?

NON-HORMONAL

Didronel® PMO

etidronate disodium/calcium carbonate

The power to restore bone and reduce vertebral fracture[1,2]

ABBREVIATED PRESCRIBING INFORMATION: PRESENTATION Didronel PMO is a two component therapy consisting of 14 Didronel 400 mg tablets and 76 Cacit 500 mg effervescent tablets. Each Didronel 400mg tablet contains 400 mg of etidronate disodium, USP. Each Cacit 500 mg effervescent tablet contains 1250 mg of calcium carbonate, Ph Eur. **INDICATION** Treatment of established vertebral osteoporosis, a disease characterised by a loss of bone mass and an increased risk of fracture. **DOSAGE AND ADMINISTRATION** Didronel PMO therapy is a long-term cyclical regimen administered in 90-day cycles. Each cycle consists of Didronel 400 mg tablets for the first 14 days, followed by Cacit 500 mg effervescent tablets for the remaining 76 days. The recommended duration of therapy is up to three years. **CONTRA-INDICATIONS, WARNINGS, ETC.** *Contra-indications:* Known hypersensitivity to etidronate disodium, severe renal impairment, hypercalcaemia or hypercalciuria, clinically overt osteomalacia. Use in pregnancy and lactation. *Precautions and warnings:* Didronel PMO therapy should be withheld from patients with enterocolitis. Caution should be taken in patients with impaired renal function, or a history of renal stone formation. Hyperphosphataemia has been observed, although no adverse effects have been traced to this, and it does not constitute grounds for discontinuing therapy. *Interactions with other drugs:* Food in the stomach or upper gastrointestinal tract may reduce absorption of etidronate disodium. Mineral supplements or antacids should not be taken within two hours of dosing etidronate disodium. Cacit may interfere with absorption of some drugs. *Side-effects:* The most common side-effects are gastrointestinal disturbance. Other rarely reported side-effects include mild leg cramps, hypersensitivity, haematological or neurological reactions. **LEGAL CATEGORY** POM. **PRODUCT LICENCE HOLDER** Procter & Gamble Pharmaceuticals UK, Limited, Lovett House, Lovett Road, Staines, Middlesex TW18 3AZ. **PRODUCT LICENCE NUMBER** 0364/0051. **BASIC NHS COST** £40.20 per 90-day therapy kit. Cacit is a trademark. Didronel is a registered trade mark. **References** 1. Storm, T. *et al.,* (1990), *New England Journal of Medicine, 322,* 1265-1271. 2. Watts, N.B. *et al.,* (1990), *New England Journal of Medicine, 323,* 73-79. Further information available on request from Procter & Gamble Pharmaceuticals UK Limited, Lovett House, Lovett Road, Staines, Middlesex TW18 3AZ. UK/API/1.4/AUG 93.

Procter & Gamble PHARMACEUTICALS

SYNTEX